Luvixasertib
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Luvixasertib
- DrugBank Accession Number
- DB19200
- Background
Luvixasertib is under investigation in clinical trial NCT05251714 (CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer).
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 498.587
Monoisotopic: 498.23793885 - Chemical Formula
- C28H30N6O3
- Synonyms
- Benzamide, n-cyclopropyl-4-(7-(((cis-3-hydroxy-3-methylcyclobutyl)methyl)amino)-5-(3-pyridinyloxy)pyrazolo(1,5-a)pyrimidin-3-yl)-2-methyl-
- N-cyclopropyl-4-(7-(((cis-3-hydroxy-3-methylcyclobutyl)methyl)amino)-5-(3-pyridinyloxy)pyrazolo(1,5-a)pyrimidin-3-yl)-2-methylbenzamide
- External IDs
- CFI 402257
- CFI-402257
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- HE97PTK3Q6
- CAS number
- 1610759-22-2
- InChI Key
- PMQUGSPFUBGJCZ-CHOKWEPUSA-N
- InChI
- InChI=1S/C28H30N6O3/c1-17-10-19(5-8-22(17)27(35)32-20-6-7-20)23-16-31-34-24(30-14-18-12-28(2,36)13-18)11-25(33-26(23)34)37-21-4-3-9-29-15-21/h3-5,8-11,15-16,18,20,30,36H,6-7,12-14H2,1-2H3,(H,32,35)/t18-,28-
- IUPAC Name
- SMILES
- CC1=CC(=CC=C1C(=O)NC1CC1)C1=C2N=C(OC3=CC=CN=C3)C=C(NC[C@H]3C[C@@](C)(O)C3)N2N=C1
References
- General References
- Not Available
- External Links
- ChemSpider
- 60600040
- BindingDB
- 50512456
- ChEMBL
- CHEMBL4469414
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data1 Active Not Recruiting Treatment Advanced Solid Cancers / Breast Cancer 1 somestatus stop reason just information to hide 1, 2 Active Not Recruiting Treatment Breast Cancer 1 somestatus stop reason just information to hide 1, 2 Recruiting Treatment Advanced Solid Tumors / Breast Cancer 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at July 08, 2024 21:16 / Updated at July 10, 2024 02:16